P/E ratio for Medifast (MED)
P/E ratio as of April 2024 (TTM): 2.76
According to Medifast's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 2.75839. At the end of 2022 the company had a P/E ratio of 9.00.
P/E ratio history for Medifast from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 9.00 | -39.72% |
| 2021 | 14.9 | -33.5% |
| 2020 | 22.5 | 35.71% |
| 2019 | 16.6 | -38.3% |
| 2018 | 26.8 | -10.46% |
| 2017 | 30.0 | 8.68% |
| 2016 | 27.6 | 50.64% |
| 2015 | 18.3 | -45.45% |
| 2014 | 33.5 | 123.41% |
| 2013 | 15.0 | -33.99% |
| 2012 | 22.7 | 118.88% |
| 2011 | 10.4 | -49.61% |
| 2010 | 20.6 | -43.34% |
| 2009 | 36.4 | 144.02% |
| 2008 | 14.9 | -7.72% |
| 2007 | 16.2 | -52.41% |
| 2006 | 34.0 | 42.63% |
| 2005 | 23.8 | 8.26% |
| 2004 | 22.0 | -60.99% |
| 2003 | 56.4 | 281.65% |
| 2002 | 14.8 | 437.37% |
| 2001 | 2.75 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -269.18% | 🇺🇸 USA |
 Abeona Therapeutics
ABEO | -1.10 | -139.71% | 🇺🇸 USA |
 Bellerophon Therapeutics
BLPH | -0.0458 | -101.66% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.